| 1 | at dz technology limited | | | | | | | 2 | 0.42% |
| 2 | home about projects services | | | | | | | 1 | 0.21% |
| 3 | drug discovery description in | | | | | | | 1 | 0.21% |
| 4 | project to expedite drug | | | | | | | 1 | 0.21% |
| 5 | embarked on a groundbreaking | | | | | | | 1 | 0.21% |
| 6 | we embarked on a | | | | | | | 1 | 0.21% |
| 7 | companies we embarked on | | | | | | | 1 | 0.21% |
| 8 | pharmaceutical companies we embarked | | | | | | | 1 | 0.21% |
| 9 | leading pharmaceutical companies we | | | | | | | 1 | 0.21% |
| 10 | with leading pharmaceutical companies | | | | | | | 1 | 0.21% |
| 11 | discovery description in collaboration | | | | | | | 1 | 0.21% |
| 12 | quantumdriven drug discovery description | | | | | | | 1 | 0.21% |
| 13 | expedite drug discovery using | | | | | | | 1 | 0.21% |
| 14 | name quantumdriven drug discovery | | | | | | | 1 | 0.21% |
| 15 | project name quantumdriven drug | | | | | | | 1 | 0.21% |
| 16 | businesses and organizations 3 | | | | | | | 1 | 0.21% |
| 17 | for businesses and organizations | | | | | | | 1 | 0.21% |
| 18 | data for businesses and | | | | | | | 1 | 0.21% |
| 19 | critical data for businesses | | | | | | | 1 | 0.21% |
| 20 | safeguarding critical data for | | | | | | | 1 | 0.21% |
| 21 | threats safeguarding critical data | | | | | | | 1 | 0.21% |
| 22 | resistant to future quantum | | | | | | | 1 | 0.21% |
| 23 | to expedite drug discovery | | | | | | | 1 | 0.21% |
| 24 | discovery using quantum computing | | | | | | | 1 | 0.21% |
| 25 | drug discovery using quantum | | | | | | | 1 | 0.21% |
| 26 | interactions and predicting drug | | | | | | | 1 | 0.21% |
| 27 | accelerate the development of | | | | | | | 1 | 0.21% |
| 28 | to accelerate the development | | | | | | | 1 | 0.21% |
| 29 | potential to accelerate the | | | | | | | 1 | 0.21% |
| 30 | the potential to accelerate | | | | | | | 1 | 0.21% |
| 31 | has the potential to | | | | | | | 1 | 0.21% |
| 32 | approach has the potential | | | | | | | 1 | 0.21% |
| 33 | innovative approach has the | | | | | | | 1 | 0.21% |
| 34 | predicting drug candidates this | | | | | | | 1 | 0.21% |
| 35 | and predicting drug candidates | | | | | | | 1 | 0.21% |
| 36 | molecular interactions and predicting | | | | | | | 1 | 0.21% |
| 37 | that is resistant to | | | | | | | 1 | 0.21% |
| 38 | simulating molecular interactions and | | | | | | | 1 | 0.21% |
| 39 | and resources required for | | | | | | | 1 | 0.21% |
| 40 | time and resources required | | | | | | | 1 | 0.21% |